改善1型糖尿病的肥胖治疗(OTID):胰高血糖素样肽1类似物联合钠-葡萄糖协同转运蛋白2抑制剂随机对照试验方案
本研究为6个月随机对照试验,计划纳入60例21至65岁、体重指数>25 kg/m²的1型糖尿病合并慢性肾脏病受试者,随机分为标准治疗、胰高血糖素样肽1受体类似物单药、钠-葡萄糖协同转运蛋白2抑制剂单药、两药联合及联合强化生活方式建议5组,主要终点为6个月时总体重较基线的百分比变化。
要点
- 美国糖尿病协会和欧洲糖尿病研究协会指南建议,肥胖2型糖尿病合并慢性肾脏病患者若单药未达代谢控制,可联合胰高血糖素样肽1受体类似物与钠-葡萄糖协同转运蛋白2抑制剂。
- 本试验在1型糖尿病合并慢性肾脏病人群中检验上述联合治疗对体重和肾脏损伤的影响。
- 主要终点为6个月时总体重较基线的百分比变化,次要终点包括血糖、血压、血脂异常、白蛋白尿等。
核心结论
- 本随机对照试验旨在研究胰高血糖素样肽1受体类似物联合钠-葡萄糖协同转运蛋白2抑制剂对1型糖尿病合并慢性肾脏病患者体重和肾脏损伤的影响,并探索各治疗相关代谢通路变化。
研究设计与样本
- 6个月随机对照试验,计划纳入60例21至65岁、体重指数>25 kg/m²的1型糖尿病合并慢性肾脏病受试者,随机分为5组。
- 5组分别为:标准治疗(对照)、胰高血糖素样肽1受体类似物单药、钠-葡萄糖协同转运蛋白2抑制剂单药、两药联合、两药联合加强化生活方式建议。
- 所有实验在Dasman糖尿病研究所进行,并经当地研究和伦理委员会批准。
- 试验注册号ClinicalTrials.gov NCT05390307,注册日期2022年5月25日。
关键数值与推荐
- 主要终点为6个月时总体重较基线的百分比变化。
- 次要终点包括血糖、血压、血脂异常、白蛋白尿的变化,达到体重减轻≥5%、≥10%和≥15%的受试者比例,以及体重指数(kg/m²)和腰围(cm)较基线的变化。
临床怎么用
- 美国糖尿病协会和欧洲糖尿病研究协会指南建议,肥胖2型糖尿病合并慢性肾脏病患者需要胰高血糖素样肽1受体类似物或钠-葡萄糖协同转运蛋白2抑制剂;若两者均未达到代谢控制,则建议联合使用这两种药物。
- 原文未据此给出针对1型糖尿病合并慢性肾脏病的推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The guidelines of the American Diabetes Association and European Association for the Study of Diabetes suggest that patients with obesity type 2 diabetics and chronic kidney disease need either glucagon-like peptide 1 receptor analogues or sodium-glucose cotransporter-2 inhibitors. If neither achieve metabolic control, then the recommendation is to combine both drugs. The evidence base for combining glucagon-like peptide 1 receptor analogues and sodium-glucose cotransporter-2 inhibitors is not well researched, and hence, the impact of the guidelines is limited. The aim of this randomized controlled trial is to test the impact of the combination of glucagon-like peptide 1 receptor analogues/sodium-glucose cotransporter-2 inhibitors on body weight and kidney damage, in patients with type 1 diabetes and chronic kidney disease. In addition, we will explore the associated changes in the metabolic pathways with each of the treatments used in this randomized controlled trial. METHODS: In this 6-month randomized control trial, 60 participants aged between 21 and 65 years, with a body mass index above 25 kg/m2, and type 1 diabetics with chronic kidney disease will be randomized to receive 1 of 5 possible treatments: (1) standard care (control), (2) glucagon-like peptide 1 receptor analogues alone, (3) sodium-glucose cotransporter-2 inhibitors alone, (4) combination of glucagon-like peptide 1 receptor analogues and sodium-glucose cotransporter-2 inhibitors and (5) combination of glucagonlike peptide 1 receptor analogues and sodium-glucose cotransporter-2 inhibitors with intensive lifestyle advice. The primary objective will be the percentage change in total body weight from baseline at 6 months. The secondary objectives are to compare the change in glycaemia; blood pressure; dyslipidaemia; albuminuria; proportion of participants reaching weight loss of ≥ 5%, ≥ 10% and ≥ 15%; and change in BMI (kg/m2) from baseline and change in waist circumference (cm). All the experiments will be conducted at the Dasman Diabetes Institute after approval from the local research and ethics committee. DISCUSSION: The present randomized controlled trial aims to investigate the impact of the combination of glucagon-like peptide 1 receptor analogues and sodium-glucose cotransporter-2 inhibitors on body weight and kidney damage in patients with type 1 diabetes mellitus and chronic kidney disease, as well as exploring the associated changes in the metabolic pathways with each of the treatments used. This study addresses the current gap in the evidence base regarding the combination of these two drugs, which is particularly relevant given the American Diabetes Association and European Association for the Study of Diabetes guidelines recommending their combined use for patients with obesity, type 2 diabetes, and chronic kidney disease who do not achieve metabolic control with either drug alone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05390307 Trial registration date - 25th May 2022.
引用
- Al-Ozairi E, Narula K, Miras AD, et al. Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial). Trials. 2024. PMID: 38365744. doi:10.1186/s13063-024-07930-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。